Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 5/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 5/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.43 |
| ▸ | PER2 | O15055 | 1/20 | 0.39 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 6/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 6/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ITGAV | P06756 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4569088 | 0.84 | KMT2A (0.46) | MEN1KMT2AKDM4E | |
| SCHEMBL4568792 | 0.76 | TSHR (0.40) | KDM4ETSHR | |
| SCHEMBL20295221 | 0.76 | KMT2A (0.45) | KMT2AKDM4E | |
| SCHEMBL2205942 | 0.76 | KMT2A (0.45) | KMT2AKDM4E | |
| SCHEMBL23116499 | 0.75 | L3MBTL1 (0.42) | KMT2AKDM4E | |
| SCHEMBL13881750 | 0.73 | TSHR (0.38) | KDM4ETSHR | |
| SCHEMBL2206399 | 0.73 | TSHR (0.38) | KDM4ETSHR | |
| SCHEMBL20295212 | 0.73 | TSHR (0.38) | KDM4ETSHR | |
| SCHEMBL19291709 | 0.73 | TSHR (0.38) | KDM4ETSHR | |
| SCHEMBL29818647 | 0.73 | TSHR (0.38) | KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10639286-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2020-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10639286-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | SCN1A 2610/4885SCN5A 3279/4885SCN9A 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.